↓ Skip to main content

Influence of riociguat treatment on pulmonary arterial hypertension

Overview of attention for article published in Herz, July 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
30 Mendeley
Title
Influence of riociguat treatment on pulmonary arterial hypertension
Published in
Herz, July 2018
DOI 10.1007/s00059-018-4697-z
Pubmed ID
Authors

R. Zhao, Y. Jiang

Abstract

Riociguat treatment might be beneficial for pulmonary arterial hypertension. However, the results of studies to date are controversial. We conducted a systematic review and meta-analysis to explore the influence of riociguat treatment on pulmonary arterial hypertension. The PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of riociguat treatment on pulmonary arterial hypertension were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. This meta-analysis was performed using the random effects model. Seven RCTs were included in the meta-analysis. Compared with a control intervention in pulmonary arterial hypertension, riociguat treatment was able to substantially improve results of the six-minute walking distance (6-MWD; standardized mean difference [SMD] = 0.53; 95% CI = 0.36-0.69; p < 0.00001), EQ-5D score (SMD = 0.35; 95% CI = 0.15-0.54; p = 0.0005), and cardiac index (SMD = 0.94; 95% CI = 0.59-1.29; p < 0.00001). The Living With Pulmonary Hypertension (LPH) score (SMD = -0.33; 95% CI = -0.50--0.17; p < 0.0001) and pulmonary vascular resistance (PVR; SMD = -0.88; 95% CI = -1.05--0.70; p < 0.00001) were significantly reduced after riociguat treatment. There was no increase in adverse events with riociguat treatment compared with the control intervention (RR = 1.04; 95% CI = 0.98-1.09; p = 0.19). Riociguat treatment for pulmonary arterial hypertension led to a significant increase in the 6‑MWD, EQ-5D score, and cardiac index, as well as a decrease in LPH score and PVR.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 17%
Researcher 5 17%
Student > Master 4 13%
Other 3 10%
Student > Postgraduate 2 7%
Other 4 13%
Unknown 7 23%
Readers by discipline Count As %
Medicine and Dentistry 8 27%
Biochemistry, Genetics and Molecular Biology 3 10%
Nursing and Health Professions 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Economics, Econometrics and Finance 2 7%
Other 5 17%
Unknown 8 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2018.
All research outputs
#18,641,800
of 23,096,849 outputs
Outputs from Herz
#326
of 444 outputs
Outputs of similar age
#251,920
of 326,353 outputs
Outputs of similar age from Herz
#6
of 9 outputs
Altmetric has tracked 23,096,849 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 444 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,353 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.